Orientador: César Roberto Esper / Banca: José Domingos Guimarães / Banca: José Octávio Jacomini / Banca: Paulo Henrique Franceschini / Banca: Francisco Guilherme Leite / Resumo: O objetivo deste trabalho foi determinar o número de células luteais bovinas, comparando fêmeas taurinas com zebuínas no início e final do ciclo estral. Foram coletados corpos lúteos de 16 fêmeas sendo 8 taurinas e 8 zebuínas, distribuídas em 4 grupos sendo coletados os ovários nos dias 3 a 5 (2 grupos: taurino e zebuíno) e 16 a 18 (2 grupos: taurino e zebuíno) do ciclo estral. Os corpos lúteos foram processados para microscopia óptica e avaliouse as células luteais pequenas, grandes e intermediárias, quanto ao número celular, diâmetro, área e perímetro. Os animais taurinos apresentaram maior quantidade de células luteais pequenas que os zebuínos no início do ciclo estral (p<O,05) e final do ciclo estral (p<O,05). Registrou-se diferença nos valores médios do diâmetro, perímetro e área das células luteais grandes, pequenas e intermediárias entre animais taurinos e zebuínos, tanto no início quanto no final do ciclo estral. / Abstract: The aim of this work was to determine the number of bovine luteal cells comparing 80S taurus females with 80S indicus females at the beginning and at the end of estrous cycle. Sixteen corpus luteum were collected in eight 80S taurus cattle and in eight 80S indicus cattle, distributed into four groups. The ovaries were collected from the third and the fifth days (two groups: 80S taurus females and 80S indicus females) and from the sixteenth and the eighteenth days (two groups: 80S taurus caUle and 80S indicus cattle) of the estrous cycle. The corpus luteum was processed to optical microscopy and the small, big and intermediate-sized luteal cells were evaluated considering the number of cells, diameter, area and perimeter. The 80S taurus females presented a bigger amount of smallluteal cells than the 80S indicus females at the beginning of the estrous cycle (p,O,05) and at the end of the estrous cycle (p<O,05). The difference in the average values of the diameter, perimeter and the area of big, small and intermediate-sized luteal cells have been registered among 80S taurus cattle and 80S indicus cattle, at the beginning and also at the end of the estrous cycle. / Doutor

A gonadotrofina coriônica equina (eCG) tem sido utilizada em programas de sincronização para inseminação artificial em tempo fixo e normalmente promove o aumento do volume do corpo lúteo e a da produção de progesterona. Além disso, esta mesma gonadotrofina pode ser utilizada para superovulação. Desse modo, hipóteses relativas aos mecanismos pelos quais gonadotrofinas exógenas alteram as funções celulares nos corpos lúteos resultantes foram formuladas. Para testar tais hipóteses, 18 vacas (Bos indicus) foram divididas em grupos: controle (n=5), estimulado (n=6) e superovulado (n=7) e a ovulação das mesmas foi sincronizada usando um protocolo já estabelecido com dispositivo de progesterona. Os animais estimulados receberam 400 UI de eCG no dia de remoção do dispositivo de progesterona e os animais superovulados 4 dias antes. No dia 7 após injeção de GnRh, os animais foram abatidos para a coleta de CLL e sangue. Análises de peso e volume de CL, concentração de progesterona (P4), bem como da expressão gênica e proteica de fatores angiogênicos e de proteínas esteroidogênicas foram realizadas. Além disso, o transcriptoma foi analisado por microarranjo. Foi observado que o volume do CL foi maior nos animais do grupo estimulado (1177,37 ± 167,07 mm3) e ainda maior nos do superovulado (1495,18 ± 137,01 mm3) quando comparados ao grupo controle (830,33 ± 234,99 mm3; p = 0,03). A concentração média de progesterona por CL nos animais do grupo estimulado foi maior que nos animais do grupo controle (5,95 ± 0,17 vs 3,69 ± 0,72 ng/ml; p = 0,03) e que nos superovulados (4,11 ± 0.73; p = 0,01). Além disso, os tratamentos com eCG aumentaram a expressão do FGFR2 e também da STAR nos animais estimulados e superovulados (p < 0,05). Quanto aos resultados do microarranjo, no total 242 transcritos foram aumentados e 111 foram diminuídos nos animais estimulados e 111 foram aumentados e 113 diminuídos nos animais superovulados em relação aos animais controle (~1,5 vezes, p 0.05). Entre os genes diferencialmente expressos, muitos estavam envolvidos na síntese de lipídios e na produção de progesterona, tais como: PPARG, HMGCR, STAR, receptores de prolactina e folistatina. Estes achados demonstraram que os tratamentos com eCG modularam a expressão gênica diferencialmente, dependendo do tratamento, e que nossos dados contribuem para entender as vias relacionadas ao aumento do volume do CL e da produção de progesterona observada após os tratamentos. Em um segundo experimento, foi realizado análises da influência do FSH na expressão de VEGF no cultivo de células da granulosa. Neste experimento foi possível observar que o FSH aumentou a expressão gênica e proteica do VEGF, colaborando com a ideia de que as gonadotrofinas têm propriedades angiogênicas. / Equine chorionic gonadotropin (eCG) has been widely used in synchronization protocol to artificial insemination program and usually promote corpus luteum (CL) volume increases and stimulates progesterone production. Furthermore the same gonadotropin can be used to superovulation protocols. Thus, hypotheses concerning the mechanisms by which exogenous gonadotropins alter cellular functions in resulting corpora lutea were formulated. To test that hypothesis, 18 (Bos indicus) cows were divided into control (n=5), stimulated (n=6) and superovulated groups (n=7). Ovulation was synchronized using a progesterone device-based protocol. Stimulated animals received 400 IU of eCG of device removal and superovulated animals received 2000 IU of eCG 4 days prior. Corpora lutea (CLL) and blood samples were collected seven days after GnRH administration. Analyses of CL weight and volume, progesterone (P4) concentration, as well as the gene and protein expression of angiogenic and steroidogenic proteins were performed. Furthermore, the transcriptome was evaluated by microarray. The CL volume was higher in superovulated (1495.18 ± 137.01) than in stimulated (1177.37 ± 167.07) cows and higher in stimulated than in the control (830.33 ± 234.99) cows, and the P4 concentration per CL was higher in stimulated (5.95 ± 0.17 ng/ml) animals than in the control (3.69 ± 0.72 ng/ml) and superovulated (4.11 ± 0.73 ng/ml; P = 0.01) animals. Overall, 242 transcripts were up-regulated and 111 transcripts were downregulated in stimulated cows (P 0.05) and 111 were up-regulated and 113 down-regulated in superovulated cows in relation to the control (1.5 fold, P 0.05). Among the differentially expressed genes, many were involved in lipid biosynthesis and progesterone production, as PPARG, HMGCR, STAR, prolactin receptors and follistatin. In conclusion, eCG modulates gene expression differently depending on the treatment. Our data contribute to the understanding of the pathways involved in increased CL volume and progesterone levels observed after eCG treatment. In a second experiment, analyzes were performed about the influence of FSH on the expression of VEGF in the culture of granulosa cells. In this experiment it was observed that FSH increases the expression of the VEGF gene and protein, these finding collaborate with the idea that gonadotrophins have angiogenic properties.

Em programas de transferência de embriões, as perdas embrionárias após a inovulação têm sido relacionadas com uma capacidade reduzida do corpo lúteo (CL) em secretar progesterona (P4), uma vez que este hormônio prepara o endométrio para a implantação e a manutenção da prenhez. Assim, o objetivo deste trabalho foi estudar a eficácia da utilização de dispositivo intravaginal contendo progesterona (CIDR®) por 14 dias em receptoras de embrião, para a indução de folículos persistentes e formação de CLs maiores do que aqueles formados com a utilização de CIDR® por 8 dias. Duzentas e setenta e oito novilhas Bos taurus x Bos indicus foram divididas em 4 grupos. As receptoras do Grupo 1 (G1, n = 70) receberam 2,0 mg de BE + 50 mg de P4 por via intramuscular (IM) no dia da colocação do CIDR® (D0), oito dias depois (D8), o dispositivo foi retirado e foi aplicado um análogo da prostaglandina F2 alfa (PGF2 alfa - 0,53 mg de Cloprostenol Sódico) IM pela manhã. No D9, foi aplicado 0,5 mg de BE IM e o D17 foi o dia da inovulação. Os animais do Grupo 2 (G2, n = 71) receberam 2,0 mg de BE + 50 mg de P4 no dia da colocação do CIDR® (D0), todavia, esses animais receberam 2 aplicações de PGF2 alfa, uma no início do tratamento e outra 5 dias depois. Nestes animais, o CIDR® foi mantido por 14 dias; assim, no D15 foi aplicado 0,5 mg de BE e o dia da inovulação, foi o D23. No Grupo 3 (G3, n = 67), o tratamento foi semelhante ao do G2, no entanto a PGF2 alfa foi aplicada uma única vez, 5 dias após o início do tratamento. No Grupo 4 (G4, n = 70), o tratamento foi semelhante ao do G2, tendo os animais recebido 2 aplicações de PGF2 alfa, uma no dia da colocação do CIDR® e outra no dia da retirada. A avaliação ultrassonográfica dos ovários foi realizada um dia após a retirada do CIDR® e no dia da inovulação, quando foram colhidas amostras de sangue para dosagem de P4. O diâmetro médio do folículo dominante (FD) foi maior nos grupos G2, G3 e G4 quando comparado com o grupo G1. A área do CL, a concentração plasmática de P4 e a taxa de aproveitamento foram maiores nos grupos G2 e G3 que no grupo G1, enquanto o grupo G4 não diferiu estatisticamente dos demais. A taxa de concepção nos grupos G2 e G3 foi inferior àquela do grupo G1, mas não diferiu entre o grupo G4 e os demais. A taxa de prenhez não apresentou diferença estatística entre os grupos. Esses resultados sugerem que a utilização de CIDR® por tempo prolongado, quando associada à aplicação de PGF2 alfa no início do tratamento, é eficaz na formação de folículos persistentes, que resultam em CLs aumentados e com maior capacidade de secretar P4 . No entanto, ao contrário do esperado, a taxa de concepção foi reduzida nos grupos em que o tratamento visava a formação de folículos persistentes. / Embryo losses in cattle embryo transfer programs have been related to a corpus luteum (CL) inability to secrete progesterone (P4), necessary to endometrial preparation for embryo implantation and pregnancy maintenance. Thus the objective of this experiment was to evaluate the efficacy of a treatment with progesterone-releasing intravaginal devices (CIDR®) for a period of 14 days in order to induce the formation of a persistent follicle and a CL of larger diameter than the ones produced during the conventional 8 days CIDR® treatment. Two hundred seventy-eight cross-bred Bos taurus x Bos indicus heifers were randomly allocated in four groups. Heifers in Group 1 (G1, n = 70) received 2.0 mg estradiol benzoate (EB) + 50 mg of P4 at the moment of CIDR® insertion (D0), a 0.53 mg injection of cloprostenol (PGF2 alfa analogous) at the time of CIDR® removal (D8) and 0.5 mg EB on D9. On D17 animals received a frozen/thawed embryo by direct transfer. Heifers in Group 2 (G2, n = 71) received a CIDR® device combined with 2.0 mg of EB + 50 mg of P4 (D0). Animals of this group received 2 injections of PGF2 alfa, one on D0 and the other on D5. The CIDR® was removed on D14. A 0.5 mg injection of EB was administered on D15. The treatment in Group 3 (G3, n = 67) was similar to G2, except by the fact that a single injection of PGF2 alfa was administered on D5. Treatment performed on animals of Group 4 was similar to the one performed on G2. However, animals of this group received two injections of PGF2 alfa, one at the time of CIDR® insertion and the other at the moment of it?s removal. Ovarian ultrasonography was performed on the day after CIDR® removal and at the day of embryo transfer. Blood samples for P4 analysis were also collected on the day of embryo transfer. Mean diameter of the dominant follicle was larger in heifers in G2, G3 and G4 when compared to G1. The CL area, plasma progesterone concentrations and recipient selection rate was greater in G2 and G3 than in G1, but G4 was not different of the other groups. Conception rates were lower in G2 and G3 when compared to G1. No differences between groups were found regarding to the pregnancy rates. These results suggest that a CIDR® long-term treatment, when associated with PGF2 alfa in the beggining of the treatment is efficient to stimulate the formation of a persistent follicle, resulting in a larger CL which provides higher P4 concentration. However, the induction of a persistent follicle had a negative effect on the conception rates which was not expected.

Em programas de transferência de embriões, as perdas embrionárias após a inovulação têm sido relacionadas com uma capacidade reduzida do corpo lúteo (CL) em secretar progesterona (P4), uma vez que este hormônio prepara o endométrio para a implantação e a manutenção da prenhez. Assim, o objetivo deste trabalho foi estudar a eficácia da utilização de dispositivo intravaginal contendo progesterona (CIDR®) por 14 dias em receptoras de embrião, para a indução de folículos persistentes e formação de CLs maiores do que aqueles formados com a utilização de CIDR® por 8 dias. Duzentas e setenta e oito novilhas Bos taurus x Bos indicus foram divididas em 4 grupos. As receptoras do Grupo 1 (G1, n = 70) receberam 2,0 mg de BE + 50 mg de P4 por via intramuscular (IM) no dia da colocação do CIDR® (D0), oito dias depois (D8), o dispositivo foi retirado e foi aplicado um análogo da prostaglandina F2 alfa (PGF2 alfa - 0,53 mg de Cloprostenol Sódico) IM pela manhã. No D9, foi aplicado 0,5 mg de BE IM e o D17 foi o dia da inovulação. Os animais do Grupo 2 (G2, n = 71) receberam 2,0 mg de BE + 50 mg de P4 no dia da colocação do CIDR® (D0), todavia, esses animais receberam 2 aplicações de PGF2 alfa, uma no início do tratamento e outra 5 dias depois. Nestes animais, o CIDR® foi mantido por 14 dias; assim, no D15 foi aplicado 0,5 mg de BE e o dia da inovulação, foi o D23. No Grupo 3 (G3, n = 67), o tratamento foi semelhante ao do G2, no entanto a PGF2 alfa foi aplicada uma única vez, 5 dias após o início do tratamento. No Grupo 4 (G4, n = 70), o tratamento foi semelhante ao do G2, tendo os animais recebido 2 aplicações de PGF2 alfa, uma no dia da colocação do CIDR® e outra no dia da retirada. A avaliação ultrassonográfica dos ovários foi realizada um dia após a retirada do CIDR® e no dia da inovulação, quando foram colhidas amostras de sangue para dosagem de P4. O diâmetro médio do folículo dominante (FD) foi maior nos grupos G2, G3 e G4 quando comparado com o grupo G1. A área do CL, a concentração plasmática de P4 e a taxa de aproveitamento foram maiores nos grupos G2 e G3 que no grupo G1, enquanto o grupo G4 não diferiu estatisticamente dos demais. A taxa de concepção nos grupos G2 e G3 foi inferior àquela do grupo G1, mas não diferiu entre o grupo G4 e os demais. A taxa de prenhez não apresentou diferença estatística entre os grupos. Esses resultados sugerem que a utilização de CIDR® por tempo prolongado, quando associada à aplicação de PGF2 alfa no início do tratamento, é eficaz na formação de folículos persistentes, que resultam em CLs aumentados e com maior capacidade de secretar P4 . No entanto, ao contrário do esperado, a taxa de concepção foi reduzida nos grupos em que o tratamento visava a formação de folículos persistentes. / Embryo losses in cattle embryo transfer programs have been related to a corpus luteum (CL) inability to secrete progesterone (P4), necessary to endometrial preparation for embryo implantation and pregnancy maintenance. Thus the objective of this experiment was to evaluate the efficacy of a treatment with progesterone-releasing intravaginal devices (CIDR®) for a period of 14 days in order to induce the formation of a persistent follicle and a CL of larger diameter than the ones produced during the conventional 8 days CIDR® treatment. Two hundred seventy-eight cross-bred Bos taurus x Bos indicus heifers were randomly allocated in four groups. Heifers in Group 1 (G1, n = 70) received 2.0 mg estradiol benzoate (EB) + 50 mg of P4 at the moment of CIDR® insertion (D0), a 0.53 mg injection of cloprostenol (PGF2 alfa analogous) at the time of CIDR® removal (D8) and 0.5 mg EB on D9. On D17 animals received a frozen/thawed embryo by direct transfer. Heifers in Group 2 (G2, n = 71) received a CIDR® device combined with 2.0 mg of EB + 50 mg of P4 (D0). Animals of this group received 2 injections of PGF2 alfa, one on D0 and the other on D5. The CIDR® was removed on D14. A 0.5 mg injection of EB was administered on D15. The treatment in Group 3 (G3, n = 67) was similar to G2, except by the fact that a single injection of PGF2 alfa was administered on D5. Treatment performed on animals of Group 4 was similar to the one performed on G2. However, animals of this group received two injections of PGF2 alfa, one at the time of CIDR® insertion and the other at the moment of it?s removal. Ovarian ultrasonography was performed on the day after CIDR® removal and at the day of embryo transfer. Blood samples for P4 analysis were also collected on the day of embryo transfer. Mean diameter of the dominant follicle was larger in heifers in G2, G3 and G4 when compared to G1. The CL area, plasma progesterone concentrations and recipient selection rate was greater in G2 and G3 than in G1, but G4 was not different of the other groups. Conception rates were lower in G2 and G3 when compared to G1. No differences between groups were found regarding to the pregnancy rates. These results suggest that a CIDR® long-term treatment, when associated with PGF2 alfa in the beggining of the treatment is efficient to stimulate the formation of a persistent follicle, resulting in a larger CL which provides higher P4 concentration. However, the induction of a persistent follicle had a negative effect on the conception rates which was not expected.

<p>Proteases of the plasminogen activator (PA) and the matrix metalloproteinase (MMP) enzyme systems are expressed in the ovulatory follicle and in the developing corpus luteum (CL). However, the functional role of these extracellular degrading protease systems in the ovulatory and CL development processes remains elusive. The first aim of this thesis was to develop a mouse model to study gonadotropin-induced CL formation. The second aim was to study the involvement of the PA and the MMP systems in gonadotropin-induced ovulation, and in CL formation and function.</p><p>A mouse model for gonadotropin-induced CL formation was developed in order to control the timing of CL formation. In this model, immature mice were induced to ovulate by administrating gonadotropins and the endogenous prolactin surges were mimicked by administration of prolactin twice daily from day 2 of CL development. We observed that steroidogenic acute regulatory protein (StAR) mRNA was highly expressed at days 3 and day 6 of CL development and the levels remained high until late stages of CL regression.</p><p>Since mice lacking plasminogen (plg-/-) only have a 14% reduction of ovulation efficiency, our hypothesis was that the MMP system could compensate for the loss of plasminogen. When administrating the MMP-inhibitor galardin to gonadotropin-primed ovulating mice, we found that wild-type mice (plg+/+ and C67BL/J6) and heterozygous mice (plg+/-) had an 18-20% reduction in ovulation efficiency as compared to untreated mice.</p><p>Two models for CL formation, the adult pseudopregnant (psp) mouse model and a model whereby immature gonadotropin-primed mice were treated with prolactin, were used to study the formation and function of the CL in plg-/- mice treated with galardin. At day 3 of CL development, we found no alterations other than a slightly lower number of CL in plg-/- mice. This is most likely a secondary effect of the lower ovulation efficiency found in these mice. On the other hand, we found a 54% reduction in serum progesterone levels in plg-/- mice and a 37% reduction in the plg+/- mice as compared to wild type mice. At day 6 of CL development we saw a 45 % reduction of serum progesterone level in the plg-/- mice and a 22 % reduction in the plg+/- mice. A similar trend was observed at day 3 of CL development in immature gonadotropinprimed mice treated with prolactin. Galardin treatment did not alter the results significantly and the CLs were healthy and viable in these mice.</p><p>In conclusion, our data suggest that both plasminogen and MMPs, alone or in combination, are dispensable for ovulation and for the formation of a viable CL under the conditions used in this study. The reduced serum progesterone levels observed in the plg-/- mice did not appear to be a result of defective CL formation. Instead, plasmin may have a novel role in the maintenance of luteal function. StAR expression may also be a good marker for CL development and regression in mice.</p>

Experiments were conducted to determine whether endogenous progesterone regulates synthesis and/or secretion of luteal oxytocin (OT). In experiment 1, mature ewes (n=5 per group) were assigned randomly to control or mifepristone (RU 486) treatment groups. Ewes were injected twice daily s.c. with vehicle or 10 mg RU 486 from days 5-7 of the estrous cycle (estrus=day 0). On day 8, following an i.v. prostaglandin F₂α (250 μg cloprostenol) challenge, venous samples were collected at frequent intervals to determine plasma OT concentrations. Plasma OT in RU 486-treated animals did not differ significantly from those of the control animals (P>0.05). In Experiment 2, ewes were injected s.c. daily with vehicle or 175 mg RU 486 from days 2-5 of the estrous cycle followed by a prostaglandin F₂α (250 μg cloprostenol) challenge on day 6. Four of five RU 486-treated ewes exhibited "split-estrus" (estrous behavior through 36 hours and again 84 to 108 hours after the onset of initial estrus). There was no significant difference in mean plasma OT or progesterone levels between treatment groups (P>0.05). Mean mature corpus luteum (CL) weights of control and RU 486-treated ewes on day 6 did not differ (394.8 ± 28.8 vs. 319.5 ± 48.3 mg; P>0.05). Mifepristone-treated ewes contained mature CL, new CL (2 of 4 ewes), and/or preovulatory follicles (≥ 10 mm, 2 of 4 ewes). Average interestrous interval for RU 486-treated ewes was 9 days longer than that of control animals (26.2 ± 2.9 vs. 17 ± 0.5 days; P<0.025). A subsequent study was conducted to determine the effects of gonadotropin-releasing hormone (GnRH)-stimulated release of luteinizing hormone (LH) on luteal OT and progesterone production in beef heifers. Ten heifers with normal estrous cycles were assigned randomly in equal numbers to a control and treatment group. On day 2 of the estrous cycle (estrus=day 0) heifers were injected with either physiological saline or 100 pg GnRH every 4 hours for 56 hours. Samples were collected 0 min pre- and 180 min post-GnRH challenge for progesterone analysis. Sixty hours after the initial injection of GnRH or saline, heifers were challenged with an i.v. injection of 500 pg prostagland in F₂α (cloprostenol) and blood was collected at frequent intervals for OT analysis. Luteal OT synthesis was suppressed (P<0.01) in heifers receiving repeated injections of GnRH compared to saline-treated control animals. Progesterone secretion was significantly greater in saline-treated animals compared to GnRH-treated animals pre- and post-challenge (1.0 ± 0.06 vs. 0.93 ± 0.11 ng/ml and 1.16 ± 0.05 vs. 0.96 ± 0.13 ng/ml, respectively; P<0.05). / Graduation date: 2003

To determine whether membrane-related events may be involved in attenuated luteal function after gonadotropin-releasing hormone (GnRH) administration, corpora lutea (CL) were removed from 10 beef heifers on day 7 of the estrous cycle after i.v. injection of GnRH or saline on day 2 of the cycle. Luteal slices were incubated with saline (control), luteinizing hormone (LH) or 8-bromo-cAMP for 2 h. In vivo administration of GnRH reduced LH and cAMP-stimulated progesterone production by tissue (p<0.01), but basal progesterone production was not affected (p>0.05). Luteal adenylyl cyclase activity did not differ between saline and GnRH-treated animals (p>0.05). Results of this experiment suggested that GnRH-induced alteration of bovine luteal function may be due to an effect distal to the point of cAMP accumulation. To explore further the effect of GnRH on luteal cell function, 10 heifers were injected with saline or GnRH and CL removed as above. Dissociated (mixed) and small luteal cells (SC) were cultured overnight, then incubated for 2 h with medium alone (control), LH or cAMP. In vitro treatment with LH and cAMP increased progesterone in the medium relative to controls (p<0.01), however, there was no effect of GnRH injection on progesterone production (p>0.05) nor in the percentage of large cells (LC) present in the mixed cell cultures (p=0.95). It has been previously found that the ratio of LC to SC increases in GnRH-treated animals. Many LC can be ruptured during dissociation of the CL, and it is possible that this procedure altered the number of LC, such that any differences that may have existed between the saline and GnRH-exposed CL were minimized. These data suggest that differences in the LC to SC ratio may indeed account for attenuated luteal function after exposure to GnRH. To examine if early administration of GnRH alters response of the CL to prostaglandin (PG) Fav beef heifers were injected with saline or GnRH on day 2 of the cycle (n=4/group), then injected with PGF[subscript 2��], on day 8 and the CL removed 60 min later. Blood samples were collected for oxytocin (OT) analysis at frequent intervals after PGF[subscript 2��], injection and for progesterone at 0 and 60 min. Induction of the early response gene c-jun or release of OT by PGF[subscript 2��], was not altered by GnRH injection (p>0.05). Injection of PGF[subscript 2��], decreased serum progesterone by 60 min post-injection (p<0.05), but was also unaffected by GnRH (p>0.05). These data support the hypotheses that c-jun expression and OT release are involved in PGF[subscript 2��]-induced luteolysis, but early administration of GnRH did not affect these processes. / Graduation date: 1996

Graduation date: 1995

Graduation date: 1995

The present investigation was designed to further our understanding of the interaction of pituitary (luteinizing hormone, LH) and placental (chorionic gonadotropin, CG) gonadotropins with the primate corpus luteum. Studies were performed (1) to characterize the LH/CG receptor population in the